Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02972788 · ClinicalTrials.gov registry record · Early Phase 1
Effect of Enamel Matrix Proteins on Clinical Attachment Level and Alveolar Bone in Periodontal Maintenance Patients
A Early Phase 1 study of Periodontal Bone Loss, sponsored by University of Nebraska.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT02972788 is a Early Phase 1 study of Periodontal Bone Loss that has completed, run by University of Nebraska. The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02972788, a Early Phase 1 study of Periodontal Bone Loss, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to determine the effect of enamel matrix protein derivative on an inflamed, periodontal-involved tooth. The hypothesis to be studied is that enamel matrix derivative protein with increase the clinical attachment level is localized sites of advanced periodontal disease.
Conditions Studied
Interventions
- OTHER Saline
- DRUG Enamel Matrix Proteins Derivative
Study Locations (1)
Nebraska
- University of Nebraska Medical Center, College of Dentistry - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2017-02-01 |
| Est. Completion | 2018-09-20 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02972788
The ClinicalTrials.gov registry entry for NCT02972788 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Periodontal Bone Loss appearing as the primary indexed condition, and to 2 interventions - of which Saline is the first listed.
NCT02972788 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.
Frequently Asked Questions
What is clinical trial NCT02972788 about?
NCT02972788 is a clinical study titled "Effect of Enamel Matrix Proteins on Clinical Attachment Level and Alveolar Bone in Periodontal Maintenance Patients". The purpose of the study is to determine the effect of enamel matrix protein derivative on an inflamed, periodontal-involved tooth. The hypothesis to be studied is that enamel matrix derivative protein with increase the clinical attachment level is localized sites of advanced periodontal disease.
What is the current status of trial NCT02972788?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 50 participants. The study started on 2017-02-01. Estimated completion is 2018-09-20.
What conditions does trial NCT02972788 study?
This clinical trial studies the following conditions: Periodontal Bone Loss.
What interventions are being tested in trial NCT02972788?
The interventions under investigation include: Saline (OTHER), Enamel Matrix Proteins Derivative (DRUG).
Who is sponsoring clinical trial NCT02972788?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02972788 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.